Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110- FGFR1 Rearrangement

Oncologist. 2017 Apr;22(4):480-483. doi: 10.1634/theoncologist.2016-0354. Epub 2017 Feb 27.

Abstract

This brief communication reports on a patient with an exceedingly rare "8p11 (eight-p-eleven) myeloproliferative syndrome" (EMS) with CEP110-FGFR1 rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by increasing blood counts and reducing the need for transfusions. This report demonstrates that the second-generation TKI may provide a therapeutic option for elderly and frail EMS patients who cannot be offered aggressive therapy, including allogeneic hematopoietic cell transplantation. The Oncologist 2017;22:480-483.

Keywords: Acute myeloid leukemia; CEP110‐FGFR1 fusion protein; Dasatinib; Eosinophilia; Imatinib.

Publication types

  • Case Reports

MeSH terms

  • Cell Cycle Proteins / genetics*
  • Chromosomes, Human, Pair 8 / genetics
  • Dasatinib / administration & dosage
  • Down Syndrome / drug therapy*
  • Down Syndrome / genetics
  • Down Syndrome / pathology
  • Female
  • Humans
  • Leukemoid Reaction / drug therapy*
  • Leukemoid Reaction / genetics
  • Leukemoid Reaction / pathology
  • Middle Aged
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / pathology
  • Oncogene Proteins, Fusion / genetics
  • Protein Kinase Inhibitors / administration & dosage
  • Quality of Life
  • Receptor, Fibroblast Growth Factor, Type 1 / genetics*
  • Translocation, Genetic / genetics

Substances

  • CNTRL protein, human
  • Cell Cycle Proteins
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • FGFR1 protein, human
  • Receptor, Fibroblast Growth Factor, Type 1
  • Dasatinib

Supplementary concepts

  • Myeloproliferative Syndrome, Transient